Animals were assigned to four different treatment groups: saline, bleomycin + vehicle, bleomycin + VEN-201, and bleomycin + VEN-20... Ventoux Biosciences Show all Status: Preclinical. Potential: Aims to be the first disease-modifying, non-surgical pharmacologic therapy to slow progression in early stages and reduce recurrence after surgery. Results: In mouse models of skin fibrosis, daily injections reduced tissue thickness, collagen density, and overall remodeling. Synapse - Global Drug Intelligence Database +4 2. Spinal Cord Injury (SCI) Ventoux recently launched a program to evaluate VEN-201 in treating CNS fibrosis. Yahoo Finance Focus: Targeting the "fibrotic core" or scar that forms after injury and blocks axonal regrowth. Goal: To reduce scarring and create an environment that supports functional recovery and neural regeneration. Ventoux Biosciences +2 📈 Development Milestones Founded: 2022 by Kurt Harrington, a patient and pharmaceutical industry veteran. Patent: Secured a U.S. patent in late 2025 for its novel therapy targeting Dupuytren's and other fibrotic disorders. Future Timeline: The company is currently moving through ex vivo human tissue studies and fundraising to reach
It was then that Specter realized VEX-201 wasn't just a mission; it was a strategic gambit. Dr. Nakamura had coded the device to reveal a backdoor in every piece of modern software, essentially handing the reins of global digital dominance to whoever controlled the device. venx-201
Based on standard naming conventions in technical documentation, appears to be a hypothetical or internal course code (likely for a subject titled "Ventures 201" , "Ventilation Systems 201" , or "Vendor Management 201" ). Animals were assigned to four different treatment groups: